Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Kantarjian HM, Talpaz M . Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias Semin Oncol 2001 5: 9–18

    Article  Google Scholar 

  2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031–1037

    Article  CAS  Google Scholar 

  3. Goldman JM, Druker BJ . Chronic myeloid leukemia: current treatment options Blood 2001 98: 2039–2042

    Article  CAS  Google Scholar 

  4. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B . Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 2002 346: 645–652

    Article  CAS  Google Scholar 

  5. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ . STI571: a paradigm of new agents for cancer therapeutics J Clin Oncol 2002 20: 325–334

    Article  CAS  Google Scholar 

  6. Burton C, Azzi A, Kerridge I . Adverse events after imatinib mesylate therapy N Engl J Med 2002 346: 712–713

    Article  PubMed  Google Scholar 

  7. Elliott MA, Mesa RA, Tefferi A . Adverse events after imatinib mesylate therapy N Engl J Med 2002 346: 713

    Google Scholar 

  8. O'Brien SG, Peng B, Dutrix C, Mehring G, Milosavljev S, Capdeville R, Fischer T . A pharmacokinetic interaction of Glivec and simvastatin, a cytochrome 3A4 substrate, in a patients with chronic myeloid leukemia Blood 2001 98 (Suppl.): 141a (593)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohyashiki, K., Kuriyama, Y., Nakajima, A. et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 16, 2160–2161 (2002). https://doi.org/10.1038/sj.leu.2402702

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402702

This article is cited by

Search

Quick links